Finnikin Samuel, Willis Brian, Khatib Rani, Evans Tim, Marshall Tom
Department of Applied Health Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Department of Applied Health Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
BJGP Open. 2025 Jul 23;9(2). doi: 10.3399/BJGPO.2024.0258. Print 2025.
Adherence to statins for the primary prevention of cardiovascular disease (CVD) is low. There is evidence that some facets of the initiation consultation, or the initiating clinician, are associated with adherence. CVD risk estimation is fundamental to statin initiation and shared decision making (SDM), because the benefits of statins are proportional to CVD risk. Absence of a recorded CVD score before statin initiation therefore indicates that SDM is unlikely.
To investigate whether SDM, using the CVD risk score as a proxy measure, is associated with adherence to statins and CVD outcomes.
DESIGN & SETTING: A retrospective cohort study using a database of English primary care records.
The cohort will include statin-naïve patients aged 40-84 years initiated on statins for primary prevention between 2017 and 2020, categorised by the presence or absence of a CVD risk score at statin initiation. Statin adherence and persistence will be determined from subsequent statin prescriptions. Multivariable modelling, accounting for potential confounders, will determine the association between a recorded CVD risk score and subsequent statin adherence and with statin persistence. A secondary analysis will investigate the relationship to subsequent CVD outcomes and death.
This research uses a record of CVD risk score as a proxy for SDM, to investigate the link between SDM and medication adherence. It will shed light on the relationship between how the initiation consultation is performed and subsequent adherence and persistence with treatment.
他汀类药物用于心血管疾病(CVD)一级预防的依从性较低。有证据表明,起始咨询的某些方面或起始临床医生与依从性有关。CVD风险评估是他汀类药物起始治疗和共同决策(SDM)的基础,因为他汀类药物的益处与CVD风险成正比。因此,在开始使用他汀类药物之前没有记录CVD评分表明不太可能进行共同决策。
调查以CVD风险评分作为替代指标的共同决策是否与他汀类药物的依从性及CVD结局相关。
一项使用英国初级保健记录数据库的回顾性队列研究。
该队列将包括2017年至2020年间开始使用他汀类药物进行一级预防的40-84岁初治他汀类药物患者,根据开始使用他汀类药物时是否存在CVD风险评分进行分类。他汀类药物的依从性和持续性将根据后续的他汀类药物处方来确定。多变量建模将考虑潜在的混杂因素,以确定记录的CVD风险评分与后续他汀类药物依从性以及他汀类药物持续性之间的关联。二次分析将调查与后续CVD结局和死亡的关系。
本研究使用CVD风险评分记录作为共同决策的替代指标,以调查共同决策与药物依从性之间的联系。它将阐明起始咨询的实施方式与后续治疗依从性和持续性之间的关系。